Trials / Recruiting
RecruitingNCT07206758
Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
A Phase I Study Evaluating the Safety, Efficacy, Pharmacokinetics and Pharmacokinetics of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-2173 Injection | SHR-2173 injection treatment |
Timeline
- Start date
- 2025-11-12
- Primary completion
- 2026-06-01
- Completion
- 2026-11-01
- First posted
- 2025-10-03
- Last updated
- 2025-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07206758. Inclusion in this directory is not an endorsement.